Su-Ying Liang

Su-Ying Liang

Auto-generated profile, based on publicly available information

Su-Ying Liang

Palo Alto Medical Foundation Research Institute, Sutter Health’s Center for Health Systems Research, Palo Alto, California

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2023 in Radiology
Verified
Journal Article
Closed access
ECEmily F Conant
Emily F Conant
MTMelinda M. Talley
Melinda M. Talley
CPChirag R. Parghi
Chirag R. Parghi
BSBryant C. Sheh
Bryant C. Sheh
SLSu-Ying Liang
Su-Ying Liang
NANila Alsheik
Nila Alsheik
Background The use of digital breast tomosynthesis (DBT) is increasing over digital mammography (DM) following studies demonstrating lower recall rates (RRs) and higher cancer detection rates (CDRs). However, inconsistent interpretation of evidence on the risks and benefits of mammography has resulted in varying screening mammography recommendations. Purpose To evaluate screening outcomes among women in the United States who underwent routine DM or DBT mammographic screening. Materials and Methods This retrospective cohort study included women aged 40-79 years who underwent DM or DBT screening mammograms between January 2014 and December 2020. Outcomes of RR, CDR, positive predictive value of recall (PPV1), biopsy rate, and positive predictive value of biopsy (PPV3) were compared between DM and DBT with use of adjusted multivariable logistic regression models. Results A total of 2 528 063 screening mammograms from 1 100 447 women (mean age, 57 years ± 10 [SD]) were included. In crude analyses, DBT (1 693 727 screening mammograms vs 834 336 DM screening mammograms) demonstrated lower RR (10.3% [95% CI: 10.3, 10.4] for DM vs 8.9% [95% CI: 8.9, 9.0] for DBT; P < .001) and higher CDR (4.5 of 1000 screening mammograms [95% CI: 4.3, 4.6] vs 5.3 of 1000 [95% CI: 5.2, 5.5]; P < .001), PPV1 (4.3% [95% CI: 4.2, 4.5] vs 5.9% [95% CI: 5.7, 6.0]; P < .001), and biopsy rates (14.5 of 1000 screening mammograms [95% CI: 14.2, 14.7] vs 17.6 of 1000 [95% CI: 17.4, 17.8]; P < .001). PPV3 was similar between cohorts (30.0% [95% CI: 29.2, 30.9] for DM vs 29.3% [95% CI: 28.7, 29.9] for DBT; P = .16). After adjustment for age, breast density, site, and index year, associations remained stable with respect to statistical significance. Conclusion Women undergoing digital breast tomosynthesis had improved screening mammography outcomes compared with women who underwent digital mammography. © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Bae and Seo in this issue.

1 January 2022 in JMIR Human Factors
Verified
Journal Article
Open access
SLSu-Ying Liang
Su-Ying Liang
CSCheryl D Stults
Cheryl D Stults
VJVeena G Jones
Veena G Jones
QHQiwen Huang
Qiwen Huang
JSJeremy Sutton
Jeremy Sutton
ACAlbert S Chan
Albert S Chan
Background: Behavioral economics-based techniques have been an increasingly utilized method in health care to influence behavior change by modifying language in patient communication (through choice architecture and the framing of words). Patient portals are a key tool for facilitating patient engagement in their health, and interventions deployed via patient portals have been effective in improving utilization of preventive health services. Objective: We examined the impacts of behavioral economics-based nudge health maintenance reminders on appointment scheduling through a patient portal and appointment completion for 2 preventive services: Medicare wellness visits and Pap smear. Methods: We conducted a retrospective observational study using electronic health record data from an integrated health care system in Northern California. Nudge health maintenance reminders with behavioral economics-based language were implemented for all sites in November 2017 for Medicare wellness visits and for selected sites in February 2018 for Pap smears. We analyzed 125,369 health maintenance reminders for Medicare wellness visits, and 585,358 health maintenance reminders for Pap smear sent between January 2017 and February 2020. The primary outcomes were rate of appointments scheduled through the patient portal and appointment completion rate. We compared the outcomes between those who received the new, behavioral economics-based health maintenance reminders (the nudge group) and those who received the original, standard health maintenance reminders (the control group). We used segmented regression with interrupted time series to assess the immediate and gradual effect of the nudge for Medicare wellness visits, and we used logistic regression to assess the association of nudge health maintenance reminders, adjusting for the propensity to receive a nudge health maintenance reminder, for Pap smear. Results: The rates of appointments scheduled through the patient portal were higher for nudge health maintenance reminder recipients than those for control health maintenance reminder recipients (Medicare wellness visits-nudge: 12,537/96,839, 13.0%; control: 2,769/28,530, 9.7%, P<.001; Pap smear-nudge: 8,239/287,149, 2.9%; control: 1,868/120,047, 1.6%; P<.001). Rates of appointment completion were higher for nudge health maintenance reminders for Pap smear (nudge: 67,399/287,149, 23.5% control: 20,393/120,047, 17.0%; P<.001) but were comparable for Medicare wellness visits (nudge: 49,835/96,839, 51.5% control: 14,781/28,530, 51.8%; P=.30). There was a marginally gradual effect of nudge on number of appointments scheduled through the patient portal for the overall Medicare wellness visits sample (at a monthly rate of 0.26%, P=.09), and a significant gradual effect among scheduled appointments (at a monthly rate of 0.46%, P=.04). For Pap smear, nudge health maintenance reminders were positively associated with number of appointments scheduled through the patient portal (overall sample: propensity adjusted odds ratio [OR] 1.62; 95% CI 1.50-1.74; among scheduled appointments: propensity adjusted OR 1.61, 95% CI 1.47-1.76) and with appointment completion (propensity adjusted OR 1.07; 1.04-1.10). Conclusions: Nudges, a behavioral economics-based approach to providing health maintenance reminders, increased the number of appointments scheduled through the patient portal for Medicare wellness visits and Pap smear. Our study demonstrates that a simple approach-framing and modifying language in an electronic message-can have a significant and long-term impact on patient engagement and access to care.

20 May 2019 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JWJuliet Elizabeth Wolford
Juliet Elizabeth Wolford
KTKrishnansu Sujata Tewari
Krishnansu Sujata Tewari
SLSu-Ying Liang
Su-Ying Liang
JBJiaru Bai
Jiaru Bai
AMAmandeep Kaur Mann
Amandeep Kaur Mann
JCJohn K. Chan
John K. Chan
5545 Background: With the December 19, 2018 regulatory approval by the US FDA of olaparib tablets as maintenance therapy for women with deleterious or suspected deleterious germline or somatic BRCAmut advanced ovarian carcinoma, it becomes important to clarify the role of PARP inhibitors in this disease. We evaluated cost-effectiveness of olaparib in the upfront (SOLO1) versus the recurrent maintenance setting (SOLO2). Methods: Data were obtained from SOLO1, the phase 3 placebo-controlled randomized upfront maintenance study among gBRCAmut patients [median PFS greater than 49.8 vs 13.8m: HR 0.30; 95% CI, 0.23-0.41; p < 0.001, NCT01844986] and SOLO2, the phase 3 placebo-controlled randomized maintenance study among gBRCAmut patients with platinum-sensitive recurrence and at least two prior lines of therapy [median PFS 19.1 vs 5.5m: HR 0.30; 95% CI, 0.22-0.41; p < 0.0001, NCT01874353]. Investigator-assessed median PFS and toxicity data from the trials were incorporated in a Markov model which transitioned patients through response, hematologic complications, non-hematologic complications, progression, and death. Using TreeAge Pro 2015, the costs of pre-treatment testing (eg. gBRCAmut), medications, and management of adverse effects were analyzed. Incremental cost-effectiveness ratios (ICERs) per month of life gained and individual PFS-life year saved (PFS-LYS) were also calculated and compared. Results: In SOLO1, cost prior to progression was 1.7x that of SOLO2 ($937,440 vs $564,451). With the extended, estimated median PFS of at least 49.8m for SOLO1 and 19.1m for SOLO2, upfront maintenance therapy was more cost-effective. SOLO 1 was associated with $312,480 PF-LYS per individual patient, while SOLO2 demonstrated $498,045 PF-LYS. Maintenance olaparib was found to be more cost-effective in the 1st-line setting, with an ICER of $12,149 per month of life gained when compared directly to SOLO2. Conclusions: Although the higher cost associated with olaparib in SOLO1 reflects the longer time patients stay on drug due to extended PFS, the ICER supports early use in the disease course as first-line maintenance therapy among women with gBRCAmut advanced ovarian carcinoma.

17 January 2024 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
PDF file
HJHuang Robert J.
Huang Robert J.
EHEdward S. Huang
Edward S. Huang
SMSatish Mudiganti
Satish Mudiganti
TCTony Chen
Tony Chen
MMMeghan C. Martinez
Meghan C. Martinez
SLSu-Ying Liang
Su-Ying Liang
Background: Gastric adenocarcinoma (GAC) is often diagnosed at advanced stages and portends a poor prognosis. We hypothesized that electronic health records (EHR) could be leveraged to identify individuals at highest risk for GAC from the population seeking routine care. Methods: This was a retrospective cohort study, with endpoint of GAC incidence as ascertained through linkage to an institutional tumor registry. We utilized 2010 to 2020 data from the Palo Alto Medical Foundation, a large multispecialty practice serving Northern California. The analytic cohort comprised individuals ages 40–75 receiving regular ambulatory care. Variables collected included demographic, medical, pharmaceutical, social, and familial data. Electronic phenotyping was based on rule-based methods. Results: The cohort comprised 316,044 individuals and approximately 2 million person-years (p-y) of observation. 157 incident GACs occurred (incidence 7.9 per 100,000 p-y), of which 102 were non-cardia GACs (incidence 5.1 per 100,000 p-y). In multivariable analysis, male sex [HR: 2.2, 95% confidence interval (CI): 1.6–3.1], older age, Asian race (HR: 2.5, 95% CI: 1.7–3.7), Hispanic ethnicity (HR: 1.9, 95% CI: 1.1–3.3), atrophic gastritis (HR: 4.6, 95% CI: 2.2–9.3), and anemia (HR: 1.9, 95% CI: 1.3–2.6) were associated with GAC risk; use of NSAID was inversely associated (HR: 0.3, 95% CI: 0.2–0.5). Older age, Asian race, Hispanic ethnicity, atrophic gastritis, and anemia were associated with non-cardia GAC. Conclusions: Routine EHR data can stratify the general population for GAC risk. Impact: Such methods may help triage populations for targeted screening efforts, such as upper endoscopy.

26 August 2024 in JNCI Cancer Spectrum
Verified
Journal Article
Open access
PDF file
ECEunji Choi
Eunji Choi
YHYue Hua
Yue Hua
CSChloe C Su
Chloe C Su
JWJulie T Wu
Julie T Wu
JNJoel W Neal
Joel W Neal
SHSummer S Han
Summer S Han
Recent therapeutic advances have improved survival among lung cancer (LC) patients, who are now at high risk of second primary lung cancer (SPLC). Hispanics comprise the largest minority in the United States, who have shown a lower LC incidence and mortality than other races, and yet their SPLC risk is poorly understood. We quantified the SPLC incidence patterns among Hispanics vs other races. We used data from the Multiethnic Cohort, a population-based cohort of 5 races (African American, Japanese American, Hispanic, Native Hawaiian, and White), recruited between 1993 and 1996 and followed through 2017. We identified patients diagnosed with initial primary lung cancer (IPLC) and SPLC via linkage to Surveillance, Epidemiology, and End Results registries. We estimated the 10-year cumulative incidence of IPLC (in the entire cohort) and SPLC (among IPLC patients). A standardized incidence ratio (SIR) was calculated as the ratio of SPLC-to-IPLC incidence by race and ethnicity. Among 202 692 participants, 6788 (3.3%) developed IPLC over 3 871 417 person-years. The 10-year cumulative IPLC incidence was lower among Hispanics (0.80%, 0.72 to 0.88) vs Whites (1.67%, 1.56 to 1.78) or Blacks (2.44%, 2.28 to 2.60). However, the 10-year SPLC incidence following IPLC was higher among Hispanics (3.11%, 1.62 to 4.61) vs Whites (2.80%, 1.94 to 3.66) or Blacks (2.29%, 1.48 to 3.10), resulting in a significantly higher SIR for Hispanics (SIR = 8.27, 5.05 to 12.78) vs Whites (SIR = 5.60, 4.11 to 7.45) or Blacks (SIR = 3.48, 2.42 to 4.84; P < .001). Hispanics have a higher SPLC incidence following IPLC than other races, which may be potentially due to better survival after IPLC and extended duration for SPLC development. Continuing surveillance is warranted to reduce racial disparities among LC survivors.

1 June 2026 in JCO Oncology Practice
Verified
Journal Article
Closed access
EDEllis C. Dillon
Ellis C. Dillon
AGAmandeep Grewal
Amandeep Grewal
SLSu-Ying Liang
Su-Ying Liang
HLHarold Luft
Harold Luft
MLMartina Li
Martina Li
MPManali I. Patel
Manali I. Patel
PURPOSE: This study evaluates a quality improvement project to improve access to specialty palliative care (PC) for individuals with advanced cancer. METHODS: A California health care organization implemented a social worker (SW)–led program to improve education about, and referrals to, PC for patients with advanced cancer at one clinic (intervention site), whereas three control sites continued usual care. We used a rigorous intention-to-treat difference-in-difference analysis to detect whether the intervention increased PC referrals (primary outcome) at the intervention versus control sites while accounting for preimplementation trends. We used multivariable logistic and Poisson regressions to compare primary and exploratory outcomes (advance care planning and end-of-life outcomes: PC visits before death, acute care use within 30 days of death, and systemic therapy within 14 days of death) in the preimplementation and postimplementation period. RESULTS: The analytic cohort included 555 patients (177 preimplementation, 378 postimplementation): 147 (26.5%) at the intervention site and 408 at control sites, with 312 (56.2%) deceased. At the intervention site postimplementation, 52 (51.5%) of 101 patients received the SW-led intervention. At the intervention site, PC referrals increased from 30.4% to 32.7% ( v 26.7% to 25.3% at control sites). PC visits increased from 21.7% to 28.7% ( v 21.4% to 22%), and among decedents, any PC visits increased from 53.1% to 75% ( v 57% to 66.9%). In adjusted multivariable analyses, the only near-significant difference-in-difference PC effect was that decedents at the intervention site had higher odds of receiving PC before death (OR, 3.09 [95% CI, 0.89 to 10.67]; P = .07). CONCLUSION: This SW-led intervention was not associated with significantly increased PC referrals. When translating evidence from trials to real-world quality improvement efforts, context and changes to the intervention may affect effectiveness.